Stock Analysis of Apexigen Inc. (APGN) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code APGN
Close 0.385
Change 0.0301 / 8.48 %
Volume 94426.00
Vol Change 62762.00 / 198.21 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Apexigen Inc.
PE (TTM)

-127.05

Very Poor
Price / Book

0.254

Excellent
Price / Sales

0

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

9574.32 K

Enterprise Value

-5121.68 K

ROA (TTM)

-0.181

Very Poor
ROE (TTM)

-0.200

Very Poor
Net Margin (TTM)

0

Poor
Revenue

%

0
Net Profit

10.90 %

-32069.00 K
Debt to Equity

0.0166

Excellent
Altman Z Score

-14.87

Very Poor
Quick Ratio

0

Poor
Cash Ratio

1.02

Indecisive


Highs/Lows of Apexigen Inc.
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.4269 9.79 % 1.54 % 0.44820.354216-Aug-2321-Aug-23
Two Week0.4075 5.50 % 3.42 % 0.450.354211-Aug-2321-Aug-23
One Month0.44 12.48 % 5.60 % 0.4650.354224-Jul-2321-Aug-23
Three Month0.3851 0 % 5.95 % 0.6280.354224-May-2321-Aug-23
Six Months1.42 72.88 % 17.48 % 1.4110.330523-Feb-2315-May-23
One year5.15 92.52 % 27.52 % 8.280.330509-Sep-2215-May-23
Two year9.841 96.09 % 29.70 % 31.350.330501-Aug-2215-May-23


Technical View of Apexigen Inc.
RSI

44.30

Neutral
MACD

-0.0156

Mild Bearish
ADX

10.95

Mild Bullish
Super Trend

0.469

Bearish
Williams %R

-67.75

Mild Bullish
CCI

-142.00

Mild Bullish


EMA 5

0.382

Strong Bullish
EMA 15

0.401

Mild Bearish
EMA 50

0.438

Strong Bearish
EMA 100

0.626

Mild Bearish
SMA 100

0.456

Strong Bearish
SMA 200

0.908

Mild Bearish
SMA 5 / 20

0.380 / 0.408

Strong Bearish
SMA 15 / 50

0.407 / 0.432

Mild Bearish
SMA 50 / 200

0.432 / 0.908

Mild Bearish




Charts of Apexigen Inc.


Returns of Apexigen Inc. with Peers
Period / StockAPGNBNOXIMVMTEM
1 Week-9.79%-5.12%8.22%-2.03%
1 Mth-12.48%-5.91%67.86%-8.23%
3 Mth0%-27.81%-61.92%-61.23%
6mth-72.88%-53.48%-78.07%-69.92%
1 Year-92.52%-67.21%-93.20%-79.43%
2 Year-96.09%-88.06%-97.11%-91.74%
5 Years---98.39%-98.71%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Apexigen Inc. with Peers
Ratio / StockAPGNBNOXIMVMTEM
PE-127.05-14.48-5.80-1491.55
P/B0.25411.3948.40-1091.76
ROA-0.181-62.90-97.28-3.70
ROE-0.200-78.65-834.540
Debt To Equity0.01660.0052-4.210.591
Revenue0
% 		22047.00
91.64 % 		0
% 		48597.00 K
146.01 %
Net Income-32069.00 K
10.90 % 		-31846.96 K
46.36 % 		-38492.00 K
5.20 % 		-26225.00 K
128.28 %


Technicals of Apexigen Inc. with Peers
Technical / StockAPGNBNOXIMVMTEM-
ADX10.959.2339.8925.60
CMF-0.095-0.091-0.1690.0332
MFI54.4436.7037.4838.35
RSI44.3038.4360.1136.71
MACD Abv SignalFalseFalseTrueTrue
Price Above 50 MAFalseFalseTrueFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Apexigen Inc.

Address : 75 Shoreway Road, San Carlos, CA, United States, 94070
Tel : 650-931-6236
URL : https://www.apexigen.com
Code : APGN, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 22_Feb_2021
Employee Count : 11

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California. As of August 23, 2023, Apexigen, Inc. operates as a subsidiary of Pyxis Oncology, Inc..


Note : All Data Generated at the End of Trading Hours (EOD Data)